Difference between revisions of "Hypereosinophilic syndrome"
Jump to navigation
Jump to search
m (→References) |
Warner-admin (talk | contribs) m (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov") |
||
Line 37: | Line 37: | ||
===References=== | ===References=== | ||
− | # '''Case report:''' Wagner LA, Speckart S, Cutter B, Gleich GJ. Treatment of FIP1L1/PDGFRA-negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody. J Allergy Clin Immunol. 2009 Jun;123(6):1407-8. Epub 2009 Apr 1. [http://www.jacionline.org/article/S0091-6749(09)00223-1/fulltext link to original article] '''contains protocol''' [https:// | + | # '''Case report:''' Wagner LA, Speckart S, Cutter B, Gleich GJ. Treatment of FIP1L1/PDGFRA-negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody. J Allergy Clin Immunol. 2009 Jun;123(6):1407-8. Epub 2009 Apr 1. [http://www.jacionline.org/article/S0091-6749(09)00223-1/fulltext link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/19342084 PubMed] |
− | # '''Retrospective:''' Strati P, Cortes J, Faderl S, Kantarjian H, Verstovsek S. Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody. Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):287-91. Epub 2012 Nov 1. [http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(12)00202-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445419/ link to PMC article] [https:// | + | # '''Retrospective:''' Strati P, Cortes J, Faderl S, Kantarjian H, Verstovsek S. Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody. Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):287-91. Epub 2012 Nov 1. [http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(12)00202-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445419/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23123105 PubMed] |
==Benralizumab monotherapy {{#subobject:39b68c|Regimen=1}}== | ==Benralizumab monotherapy {{#subobject:39b68c|Regimen=1}}== | ||
Line 63: | Line 63: | ||
'''28-day cycle for 6 or more cycles''' | '''28-day cycle for 6 or more cycles''' | ||
===References=== | ===References=== | ||
− | # '''NIAID 14-I-0081:''' Kuang FL, Legrand F, Makiya M, Ware J, Wetzler L, Brown T, Magee T, Piligian B, Yoon P, Ellis JH, Sun X, Panch SR, Powers A, Alao H, Kumar S, Quezado M, Yan L, Lee N, Kolbeck R, Newbold P, Goldman M, Fay MP, Khoury P, Maric I, Klion AD. Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N Engl J Med. 2019 Apr 4;380(14):1336-1346. [https://www.nejm.org/doi/full/10.1056/NEJMoa1812185 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557265/ link to PMC article] [https:// | + | # '''NIAID 14-I-0081:''' Kuang FL, Legrand F, Makiya M, Ware J, Wetzler L, Brown T, Magee T, Piligian B, Yoon P, Ellis JH, Sun X, Panch SR, Powers A, Alao H, Kumar S, Quezado M, Yan L, Lee N, Kolbeck R, Newbold P, Goldman M, Fay MP, Khoury P, Maric I, Klion AD. Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N Engl J Med. 2019 Apr 4;380(14):1336-1346. [https://www.nejm.org/doi/full/10.1056/NEJMoa1812185 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557265/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30943337 PubMed] |
==Cladribine & Cytarabine {{#subobject:b80308|Regimen=1}}== | ==Cladribine & Cytarabine {{#subobject:b80308|Regimen=1}}== | ||
Line 87: | Line 87: | ||
===References=== | ===References=== | ||
− | # Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer. 2005 Aug 1;104(3):541-6. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.21186/full link to original article] '''contains verified protocol''' [https:// | + | # Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer. 2005 Aug 1;104(3):541-6. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.21186/full link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/15977212 PubMed] |
==Hydroxyurea monotherapy {{#subobject:e819ce|Regimen=1}}== | ==Hydroxyurea monotherapy {{#subobject:e819ce|Regimen=1}}== | ||
Line 109: | Line 109: | ||
===References=== | ===References=== | ||
− | # Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med. 1978 Aug;89(2):167-72. [http://annals.org/article.aspx?articleid=692211 link to original article] [https:// | + | # Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med. 1978 Aug;89(2):167-72. [http://annals.org/article.aspx?articleid=692211 link to original article] [https://pubmed.ncbi.nlm.nih.gov/677578 PubMed] |
==Imatinib monotherapy {{#subobject:77c7b0|Regimen=1}}== | ==Imatinib monotherapy {{#subobject:77c7b0|Regimen=1}}== | ||
Line 165: | Line 165: | ||
===References=== | ===References=== | ||
− | # Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002 May 4;359(9317):1577-8. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)08505-7/fulltext link to original article] [https:// | + | # Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002 May 4;359(9317):1577-8. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)08505-7/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/12047970 PubMed] |
− | # Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002 Aug 15;347(7):481-7. [https://www.nejm.org/doi/full/10.1056/NEJMoa020150 link to original article] '''contains protocol''' [https:// | + | # Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002 Aug 15;347(7):481-7. [https://www.nejm.org/doi/full/10.1056/NEJMoa020150 link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/12181402 PubMed] |
− | ## '''Pooled Update:''' Cheah CY, Burbury K, Apperley JF, Huguet F, Pitini V, Gardembas M, Ross DM, Forrest D, Genet P, Rousselot P, Patton N, Smith G, Dunbar CE, Ito S, Aguiar RC, Odenike O, Gimelfarb A, Cross NC, Seymour JF. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood. 2014 Jun 5;123(23):3574-7. Epub 2014 Mar 31. [http://www.bloodjournal.org/content/123/23/3574.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047496/ link to PMC article] [https:// | + | ## '''Pooled Update:''' Cheah CY, Burbury K, Apperley JF, Huguet F, Pitini V, Gardembas M, Ross DM, Forrest D, Genet P, Rousselot P, Patton N, Smith G, Dunbar CE, Ito S, Aguiar RC, Odenike O, Gimelfarb A, Cross NC, Seymour JF. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood. 2014 Jun 5;123(23):3574-7. Epub 2014 Mar 31. [http://www.bloodjournal.org/content/123/23/3574.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047496/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24687085 PubMed]PubMed PMID: 24687085 |
− | # Pardanani A, Reeder T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ, Witzig TE, Cross NC, Tefferi A. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003 May 1;101(9):3391-7. Epub 2002 Dec 27. [http://www.bloodjournal.org/content/101/9/3391.long link to original article] '''contains protocol''' [https:// | + | # Pardanani A, Reeder T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ, Witzig TE, Cross NC, Tefferi A. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003 May 1;101(9):3391-7. Epub 2002 Dec 27. [http://www.bloodjournal.org/content/101/9/3391.long link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/12506022 PubMed] |
− | # Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, Rios MB, Letvak L, Kaled ES, Kantarjian H. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003 Jun 15;101(12):4714-6. Epub 2003 Feb 20. [http://www.bloodjournal.org/content/101/12/4714.long link to original article] '''contains verified protocol''' [https:// | + | # Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, Rios MB, Letvak L, Kaled ES, Kantarjian H. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003 Jun 15;101(12):4714-6. Epub 2003 Feb 20. [http://www.bloodjournal.org/content/101/12/4714.long link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/12595304 PubMed] |
− | # Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27;348(13):1201-14. [https://www.nejm.org/doi/full/10.1056/NEJMoa025217 link to original article] '''contains protocol''' [https:// | + | # Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27;348(13):1201-14. [https://www.nejm.org/doi/full/10.1056/NEJMoa025217 link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/12660384 PubMed] |
− | # Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M, Metcalfe DD, Dunbar C, Nutman TB. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004 Jan 15;103(2):473-8. Epub 2003 Sep 22. [http://www.bloodjournal.org/content/103/2/473.long link to original article] '''contains protocol''' [https:// | + | # Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M, Metcalfe DD, Dunbar C, Nutman TB. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004 Jan 15;103(2):473-8. Epub 2003 Sep 22. [http://www.bloodjournal.org/content/103/2/473.long link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/14504092 PubMed] |
− | # Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni N, Gottardi E, de Vivo A, Giugliano E, Iacobucci I, Paolini S, Soverini S, Rosti G, Rancati F, Astolfi C, Pane F, Saglio G, Martinelli G. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome: results of a multicenter prospective study. Haematologica. 2007 Sep;92(9):1173-9. Epub 2007 Aug 1. [http://www.haematologica.org/content/92/9/1173.long link to original article] '''contains protocol''' [https:// | + | # Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni N, Gottardi E, de Vivo A, Giugliano E, Iacobucci I, Paolini S, Soverini S, Rosti G, Rancati F, Astolfi C, Pane F, Saglio G, Martinelli G. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome: results of a multicenter prospective study. Haematologica. 2007 Sep;92(9):1173-9. Epub 2007 Aug 1. [http://www.haematologica.org/content/92/9/1173.long link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/17666373 PubMed] |
− | # Helbig G, Stella-Hołowiecka B, Majewski M, Całbecka M, Gajkowska J, Klimkiewicz R, Moskwa A, Grzegorczyk J, Lewandowska M, Hołowiecki J. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Br J Haematol. 2008 Apr;141(2):200-4. Epub 2008 Feb 26. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07033.x/full link to original article] '''contains protocol''' [https:// | + | # Helbig G, Stella-Hołowiecka B, Majewski M, Całbecka M, Gajkowska J, Klimkiewicz R, Moskwa A, Grzegorczyk J, Lewandowska M, Hołowiecki J. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Br J Haematol. 2008 Apr;141(2):200-4. Epub 2008 Feb 26. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07033.x/full link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/18307562 PubMed] |
− | # Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C, Fabarius A, Schnittger S, Grimwade D, Cross NC, Hehlmann R, Hochhaus A, Reiter A. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol. 2008 Dec;143(5):707-15. Epub 2008 Oct 17. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07294.x/full link to original article] '''contains verified protocol''' [https:// | + | # Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C, Fabarius A, Schnittger S, Grimwade D, Cross NC, Hehlmann R, Hochhaus A, Reiter A. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol. 2008 Dec;143(5):707-15. Epub 2008 Oct 17. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07294.x/full link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/18950453 PubMed] |
==Mepolizumab monotherapy {{#subobject:39b7a4|Regimen=1}}== | ==Mepolizumab monotherapy {{#subobject:39b7a4|Regimen=1}}== | ||
Line 199: | Line 199: | ||
'''21-day cycle for 8 cycles''' | '''21-day cycle for 8 cycles''' | ||
===References=== | ===References=== | ||
− | # '''GSK 100185:''' Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ; Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008 Mar 20;358(12):1215-28. Epub 2008 Mar 16. Erratum in: N Engl J Med. 2008 Jun 5;358(23): 2530. [https://www.nejm.org/doi/full/10.1056/NEJMoa070812 link to original article] '''contains verified protocol''' [https:// | + | # '''GSK 100185:''' Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ; Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008 Mar 20;358(12):1215-28. Epub 2008 Mar 16. Erratum in: N Engl J Med. 2008 Jun 5;358(23): 2530. [https://www.nejm.org/doi/full/10.1056/NEJMoa070812 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/18344568 PubMed] |
− | ## '''Update:''' Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, Haig AE, Mallett SA, Templeton DN, Ortega HG, Klion AD. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol. 2013 Feb;131(2):461-7.e1-5. Epub 2012 Oct 4. [http://www.jacionline.org/article/S0091-6749(12)01309-7/fulltext link to original article] [https:// | + | ## '''Update:''' Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, Haig AE, Mallett SA, Templeton DN, Ortega HG, Klion AD. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol. 2013 Feb;131(2):461-7.e1-5. Epub 2012 Oct 4. [http://www.jacionline.org/article/S0091-6749(12)01309-7/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/23040887 PubMed] |
==Nilotinib monotherapy {{#subobject:007581|Regimen=1}}== | ==Nilotinib monotherapy {{#subobject:007581|Regimen=1}}== | ||
Line 220: | Line 220: | ||
===References=== | ===References=== | ||
− | # '''A2101:''' Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15;354(24):2542-51. [https://www.nejm.org/doi/full/10.1056/NEJMoa055104 link to original article] [https:// | + | # '''A2101:''' Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15;354(24):2542-51. [https://www.nejm.org/doi/full/10.1056/NEJMoa055104 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16775235 PubMed] |
− | ## '''Subgroup analysis:''' Hochhaus A, le Coutre PD, Kantarjian HM, Baccarani M, Erben P, Reiter A, McCulloch T, Fan X, Novick S, Giles FJ. Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. J Cancer Res Clin Oncol. 2013 Dec;139(12):1985-93. Epub 2013 Sep 22. [http://link.springer.com/article/10.1007%2Fs00432-013-1529-7 link to original article] [https:// | + | ## '''Subgroup analysis:''' Hochhaus A, le Coutre PD, Kantarjian HM, Baccarani M, Erben P, Reiter A, McCulloch T, Fan X, Novick S, Giles FJ. Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. J Cancer Res Clin Oncol. 2013 Dec;139(12):1985-93. Epub 2013 Sep 22. [http://link.springer.com/article/10.1007%2Fs00432-013-1529-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/24057647 PubMed] |
==Peginterferon alfa-2a monotherapy {{#subobject:010d91|Regimen=1}}== | ==Peginterferon alfa-2a monotherapy {{#subobject:010d91|Regimen=1}}== | ||
Line 244: | Line 244: | ||
===References=== | ===References=== | ||
− | # '''Case series:''' Butterfield JH, Weiler CR. Use of pegylated interferon in hypereosinophilic syndrome. Leuk Res. 2012 Feb;36(2):192-7. Epub 2011 Nov 26. [http://www.lrjournal.com/article/S0145-2126(11)00469-3/fulltext link to original article] [https:// | + | # '''Case series:''' Butterfield JH, Weiler CR. Use of pegylated interferon in hypereosinophilic syndrome. Leuk Res. 2012 Feb;36(2):192-7. Epub 2011 Nov 26. [http://www.lrjournal.com/article/S0145-2126(11)00469-3/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/22118911 PubMed] |
==Ruxolitinib monotherapy {{#subobject:87790c|Regimen=1}}== | ==Ruxolitinib monotherapy {{#subobject:87790c|Regimen=1}}== | ||
Line 267: | Line 267: | ||
===References=== | ===References=== | ||
− | # '''Case report:''' Rumi E, Milosevic JD, Casetti I, Dambruoso I, Pietra D, Boveri E, Boni M, Bernasconi P, Passamonti F, Kralovics R, Cazzola M. Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. J Clin Oncol. 2013 Jun 10;31(17):e269-71. Epub 2013 Apr 29. [http://jco.ascopubs.org/content/31/17/e269.long link to original article] '''contains protocol''' [https:// | + | # '''Case report:''' Rumi E, Milosevic JD, Casetti I, Dambruoso I, Pietra D, Boveri E, Boni M, Bernasconi P, Passamonti F, Kralovics R, Cazzola M. Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. J Clin Oncol. 2013 Jun 10;31(17):e269-71. Epub 2013 Apr 29. [http://jco.ascopubs.org/content/31/17/e269.long link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/23630205 PubMed] |
[[Category:Hypereosinophilic syndrome regimens]] | [[Category:Hypereosinophilic syndrome regimens]] |
Revision as of 01:45, 25 February 2020
Section editor | |
---|---|
Sanjay R. Mohan, MD, MSCI Vanderbilt University Nashville, TN |
9 regimens on this page
9 variants on this page
|
All lines of therapy
Alemtuzumab monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Wagner et al. 2009 | Case report |
Chemotherapy
- Alemtuzumab (Campath) 30 mg IV bi-weekly
Duration not specified
References
- Case report: Wagner LA, Speckart S, Cutter B, Gleich GJ. Treatment of FIP1L1/PDGFRA-negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody. J Allergy Clin Immunol. 2009 Jun;123(6):1407-8. Epub 2009 Apr 1. link to original article contains protocol PubMed
- Retrospective: Strati P, Cortes J, Faderl S, Kantarjian H, Verstovsek S. Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody. Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):287-91. Epub 2012 Nov 1. link to original article link to PMC article PubMed
Benralizumab monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Kuang et al. 2019 (NIAID 14-I-0081) | Randomized Phase II, <20 pts (E-esc) | Placebo | Seems to have superior primary endpoint |
Chemotherapy
- Benralizumab (Fasenra) 30 mg SC once on day 1
28-day cycle for 6 or more cycles
References
- NIAID 14-I-0081: Kuang FL, Legrand F, Makiya M, Ware J, Wetzler L, Brown T, Magee T, Piligian B, Yoon P, Ellis JH, Sun X, Panch SR, Powers A, Alao H, Kumar S, Quezado M, Yan L, Lee N, Kolbeck R, Newbold P, Goldman M, Fay MP, Khoury P, Maric I, Klion AD. Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N Engl J Med. 2019 Apr 4;380(14):1336-1346. link to original article contains verified protocol link to PMC article PubMed
Cladribine & Cytarabine
back to top |
Regimen
Study | Evidence |
---|---|
Jabbour et al. 2005 | Phase II, <20 pts |
Note that the timing of drug administration is in hours in the manuscript, starting at t = 0 hours.
Chemotherapy
- Cladribine (Leustatin) 12 mg/m2/day IV continuous infusion over 120 hours, started on day 2 (total dose: 60 mg/m2)
- Cytarabine (Ara-C) 1000 mg/m2 IV over 2 hours once per day on days 1, 3, 4, 5, 6
21-day cycle, repeated once if PR/CR; see text for definition of PR
References
- Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer. 2005 Aug 1;104(3):541-6. link to original article contains verified protocol PubMed
Hydroxyurea monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Parrillo et al. 1978 | Non-randomized, <20 pts |
To be completed; treatment details are not available in the abstract.
Chemotherapy
References
- Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med. 1978 Aug;89(2):167-72. link to original article PubMed
Imatinib monotherapy
back to top |
Regimen
FDA-recommended dose |
Study | Evidence |
---|---|
Gleich et al. 2002 | Non-randomized, <20 pts |
Apperley et al. 2002 | Phase II, <20 pts |
Pardanani et al. 2002 | Phase II, <20 pts |
Cortes et al. 2003 | Phase II, <20 pts |
Cools et al. 2003 | Non-randomized, <20 pts |
Klion et al. 2003 | Non-randomized, <20 pts |
Baccarani et al. 2007 | Phase II |
Helbig et al. 2008 | Non-randomized, <20 pts |
Metzgeroth et al. 2008 | Phase II |
Dosing is as described in the Metzgeroth et al. 2008 paper.
Chemotherapy
- Imatinib (Gleevec) as follows:
- FIP1L1-PDGFRA positive patients: 100 mg PO once per day
- PDGFRB fusion positive or without known molecular aberration: 400 mg PO once per day
28-day cycle for 13 or more cycles
Subsequent treatment
- Helbig et al. 2008: Patients proceeded to a maintenance phase after 3 to 6 months of therapy which consisted of weekly dosing; dose not specified in the manuscript
References
- Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002 May 4;359(9317):1577-8. link to original article PubMed
- Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002 Aug 15;347(7):481-7. link to original article contains protocol PubMed
- Pooled Update: Cheah CY, Burbury K, Apperley JF, Huguet F, Pitini V, Gardembas M, Ross DM, Forrest D, Genet P, Rousselot P, Patton N, Smith G, Dunbar CE, Ito S, Aguiar RC, Odenike O, Gimelfarb A, Cross NC, Seymour JF. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood. 2014 Jun 5;123(23):3574-7. Epub 2014 Mar 31. link to original article link to PMC article PubMedPubMed PMID: 24687085
- Pardanani A, Reeder T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ, Witzig TE, Cross NC, Tefferi A. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003 May 1;101(9):3391-7. Epub 2002 Dec 27. link to original article contains protocol PubMed
- Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, Rios MB, Letvak L, Kaled ES, Kantarjian H. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003 Jun 15;101(12):4714-6. Epub 2003 Feb 20. link to original article contains verified protocol PubMed
- Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27;348(13):1201-14. link to original article contains protocol PubMed
- Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M, Metcalfe DD, Dunbar C, Nutman TB. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004 Jan 15;103(2):473-8. Epub 2003 Sep 22. link to original article contains protocol PubMed
- Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni N, Gottardi E, de Vivo A, Giugliano E, Iacobucci I, Paolini S, Soverini S, Rosti G, Rancati F, Astolfi C, Pane F, Saglio G, Martinelli G. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome: results of a multicenter prospective study. Haematologica. 2007 Sep;92(9):1173-9. Epub 2007 Aug 1. link to original article contains protocol PubMed
- Helbig G, Stella-Hołowiecka B, Majewski M, Całbecka M, Gajkowska J, Klimkiewicz R, Moskwa A, Grzegorczyk J, Lewandowska M, Hołowiecki J. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Br J Haematol. 2008 Apr;141(2):200-4. Epub 2008 Feb 26. link to original article contains protocol PubMed
- Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C, Fabarius A, Schnittger S, Grimwade D, Cross NC, Hehlmann R, Hochhaus A, Reiter A. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol. 2008 Dec;143(5):707-15. Epub 2008 Oct 17. link to original article contains verified protocol PubMed
Mepolizumab monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Rothenberg et al. 2008 (GSK 100185) | Phase III (E-esc) | Placebo | Superior primary endpoint |
Chemotherapy
- Mepolizumab (Nucala) 750 mg IV once on day 1
21-day cycle for 8 cycles
References
- GSK 100185: Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ; Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008 Mar 20;358(12):1215-28. Epub 2008 Mar 16. Erratum in: N Engl J Med. 2008 Jun 5;358(23): 2530. link to original article contains verified protocol PubMed
- Update: Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, Haig AE, Mallett SA, Templeton DN, Ortega HG, Klion AD. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol. 2013 Feb;131(2):461-7.e1-5. Epub 2012 Oct 4. link to original article PubMed
Nilotinib monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Kantarjian et al. 2006 (A2101) | Phase I/II, <20 pts of this subtype |
Chemotherapy
- Nilotinib (Tasigna) 400 mg PO twice per day
References
- A2101: Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15;354(24):2542-51. link to original article PubMed
- Subgroup analysis: Hochhaus A, le Coutre PD, Kantarjian HM, Baccarani M, Erben P, Reiter A, McCulloch T, Fan X, Novick S, Giles FJ. Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. J Cancer Res Clin Oncol. 2013 Dec;139(12):1985-93. Epub 2013 Sep 22. link to original article PubMed
Peginterferon alfa-2a monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Butterfield et al. 2011 | Case series |
The authors describe using peginterferon alfa-2b initially but switched to peginterferon alfa-2a when the first was "no longer available. Dosing details are not available in the abstract."
Immunotherapy
References
- Case series: Butterfield JH, Weiler CR. Use of pegylated interferon in hypereosinophilic syndrome. Leuk Res. 2012 Feb;36(2):192-7. Epub 2011 Nov 26. link to original article PubMed
Ruxolitinib monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Rumi et al. 2013 | Case report |
Chemotherapy
- Ruxolitinib (Jakafi) 15 mg PO twice per day
Duration not specified
References
- Case report: Rumi E, Milosevic JD, Casetti I, Dambruoso I, Pietra D, Boveri E, Boni M, Bernasconi P, Passamonti F, Kralovics R, Cazzola M. Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. J Clin Oncol. 2013 Jun 10;31(17):e269-71. Epub 2013 Apr 29. link to original article contains protocol PubMed